FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

Elizabeth A. Guancial, Lillian Werner, Joaquim Bellmunt, Aristotle Bamias, Toni K. Choueiri, Robert Ross, Fabio A. Schutz, Rachel S. Park, Robert J. O'Brien, Michelle S. Hirsch, Justine A. Barletta, David M. Berman, Rosina Lis, Massimo Loda, Edward C. Stack, Levi A. Garraway, Markus Riester, Franziska Michor, Philip W. Kantoff, Jonathan E. Rosenberg

Research output: Contribution to journalArticlepeer-review

Abstract

While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embedded primary UCs, 33 metastases, and 14 paired primary and metastatic tumors using the following methods: immunohistochemistry, NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and Genomic Identification of Significant Targets in Cancer software. FGFR3 immunohistochemistry staining was present in 29% of primary UCs and 49% of metastases and did not impact overall survival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in 2% of primary tumors and 9% of metastases. Mutant tumors expressed higher levels of FGFR3 mRNA than wild-type tumors (P 

Original languageEnglish (US)
Pages (from-to)835-844
Number of pages10
JournalCancer Medicine
Volume3
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Keywords

  • Biomarker
  • Bladder cancer
  • FGFR3
  • Metastatic urothelial carcinoma
  • Muscle-invasive urothelial carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder'. Together they form a unique fingerprint.

Cite this